HK Stock MarketDetailed Quotes

02181 MABPHARM-B

Watchlist

0.280
-0.010-3.45%

Market Closed Dec 20 16:08 CST

1.15BMarket Cap-5.09P/E (TTM)

MABPHARM-B Key Stats

Cash Flow

All

YOY

Hide blank lines

(Q6)Jun 30, 2024

(FY)Dec 31, 2023

(Q6)Jun 30, 2023

(FY)Dec 31, 2022

(Q6)Jun 30, 2022

(FY)Dec 31, 2021

(Q6)Jun 30, 2021

(FY)Dec 31, 2020

(Q6)Jun 30, 2020

(FY)Dec 31, 2019

Turnover

146.44%108.48M

55.87%87.16M

52.60%44.02M

-32.53%55.92M

-64.49%28.85M

--82.88M

--81.25M

----

Operating income

146.44%108.48M

55.87%87.16M

52.60%44.02M

-32.53%55.92M

-64.49%28.85M

82.88M

81.25M

Cost of sales

-127.93%-14.13M

22.45%-11.92M

43.93%-6.2M

8.36%-15.38M

34.08%-11.05M

---16.78M

---16.77M

----

Operating expenses

-127.93%-14.13M

22.45%-11.92M

43.93%-6.2M

8.36%-15.38M

34.08%-11.05M

-16.78M

-16.77M

Gross profit

149.47%94.36M

85.58%75.24M

112.57%37.82M

-38.67%40.54M

-72.40%17.79M

66.11M

64.48M

Selling expenses

-157.35%-69.6M

-73.41%-48.93M

-77.18%-27.05M

-199.41%-28.21M

---15.26M

---9.42M

----

Administrative expenses

-28.62%-60.65M

-15.57%-104.66M

1.42%-47.15M

0.08%-90.56M

-9.32%-47.83M

-37.75%-90.63M

-42.33%-43.76M

-4.52%-65.8M

-10.25%-30.74M

-49.43%-62.95M

Research and development expenses

5.43%-56.29M

16.70%-123.21M

23.67%-59.53M

43.88%-147.91M

52.29%-77.99M

-118.88%-263.57M

-168.72%-163.46M

10.26%-120.42M

-3.62%-60.83M

-50.80%-134.19M

Impairment and provision

-18.31%-756K

-261.86%-427K

---639K

---118K

----

-Other impairment is provision

-18.31%-756K

-261.86%-427K

---639K

---118K

----

Special items of operating profit

-23.90%793K

-90.25%2.21M

-89.13%1.04M

176.49%22.62M

925.84%9.59M

48.13%8.18M

-102.90%-1.16M

-81.49%5.52M

1,564.10%40.01M

226.95%29.83M

Operating profit

3.51%-92.15M

1.89%-199.78M

16.01%-95.5M

29.62%-203.63M

20.98%-113.71M

-60.13%-289.34M

-179.06%-143.89M

-8.00%-180.69M

38.75%-51.56M

-37.15%-167.31M

Financing cost

-20.45%-5.42M

-33.25%-9.58M

-44.91%-4.5M

-199.13%-7.19M

-144.99%-3.1M

39.04%-2.4M

51.71%-1.27M

48.77%-3.94M

33.95%-2.62M

-71.73%-7.7M

Special items of earning before tax

----

-5.36%-27.53M

Earning before tax

2.43%-97.57M

0.69%-209.36M

14.39%-100M

27.74%-210.82M

19.53%-116.81M

-58.01%-291.74M

-167.88%-145.16M

8.84%-184.63M

53.16%-54.19M

-32.72%-202.53M

After-tax profit from continuing operations

2.43%-97.57M

0.69%-209.36M

14.39%-100M

27.74%-210.82M

19.53%-116.81M

-58.01%-291.74M

-167.88%-145.16M

8.84%-184.63M

53.16%-54.19M

-35.24%-202.53M

Earning after tax

2.43%-97.57M

0.69%-209.36M

14.39%-100M

27.74%-210.82M

19.53%-116.81M

-58.01%-291.74M

-167.88%-145.16M

8.84%-184.63M

53.16%-54.19M

-35.24%-202.53M

Profit attributable to shareholders

2.43%-97.57M

0.69%-209.36M

14.39%-100M

27.74%-210.82M

19.53%-116.81M

-58.01%-291.74M

-167.88%-145.16M

8.84%-184.63M

53.16%-54.19M

-62.17%-202.53M

Basic earnings per share

0.00%-0.02

0.00%-0.05

33.33%-0.02

28.57%-0.05

25.00%-0.03

-75.00%-0.07

-300.00%-0.04

20.00%-0.04

66.67%-0.01

16.67%-0.05

Diluted earnings per share

0.00%-0.02

0.00%-0.05

33.33%-0.02

28.57%-0.05

25.00%-0.03

-75.00%-0.07

-300.00%-0.04

20.00%-0.04

66.67%-0.01

16.67%-0.05

Currency Unit

CNY

Accounting Standards

IAS

Audit Opinions

Unqualified Opinion

Auditor

Ernst & Young

Deloitte Guan Huang Chen Fang Certified Public Accountants

	(Q6)Jun 30, 2024	(FY)Dec 31, 2023	(Q6)Jun 30, 2023	(FY)Dec 31, 2022	(Q6)Jun 30, 2022	(FY)Dec 31, 2021	(Q6)Jun 30, 2021	(FY)Dec 31, 2020	(Q6)Jun 30, 2020	(FY)Dec 31, 2019
Turnover	146.44%108.48M	55.87%87.16M	52.60%44.02M	-32.53%55.92M	-64.49%28.85M	--82.88M	--81.25M	----	----	----
Operating income	146.44%108.48M	55.87%87.16M	52.60%44.02M	-32.53%55.92M	-64.49%28.85M	82.88M	81.25M
Cost of sales	-127.93%-14.13M	22.45%-11.92M	43.93%-6.2M	8.36%-15.38M	34.08%-11.05M	---16.78M	---16.77M	----	----	----
Operating expenses	-127.93%-14.13M	22.45%-11.92M	43.93%-6.2M	8.36%-15.38M	34.08%-11.05M	-16.78M	-16.77M
Gross profit	149.47%94.36M	85.58%75.24M	112.57%37.82M	-38.67%40.54M	-72.40%17.79M	66.11M	64.48M
Selling expenses	-157.35%-69.6M	-73.41%-48.93M	-77.18%-27.05M	-199.41%-28.21M	---15.26M	---9.42M	----	----	----	----
Administrative expenses	-28.62%-60.65M	-15.57%-104.66M	1.42%-47.15M	0.08%-90.56M	-9.32%-47.83M	-37.75%-90.63M	-42.33%-43.76M	-4.52%-65.8M	-10.25%-30.74M	-49.43%-62.95M
Research and development expenses	5.43%-56.29M	16.70%-123.21M	23.67%-59.53M	43.88%-147.91M	52.29%-77.99M	-118.88%-263.57M	-168.72%-163.46M	10.26%-120.42M	-3.62%-60.83M	-50.80%-134.19M
Impairment and provision	-18.31%-756K	-261.86%-427K	---639K	---118K	----	----	----	----	----	----
-Other impairment is provision	-18.31%-756K	-261.86%-427K	---639K	---118K	----	----	----	----	----	----
Special items of operating profit	-23.90%793K	-90.25%2.21M	-89.13%1.04M	176.49%22.62M	925.84%9.59M	48.13%8.18M	-102.90%-1.16M	-81.49%5.52M	1,564.10%40.01M	226.95%29.83M
Operating profit	3.51%-92.15M	1.89%-199.78M	16.01%-95.5M	29.62%-203.63M	20.98%-113.71M	-60.13%-289.34M	-179.06%-143.89M	-8.00%-180.69M	38.75%-51.56M	-37.15%-167.31M
Financing cost	-20.45%-5.42M	-33.25%-9.58M	-44.91%-4.5M	-199.13%-7.19M	-144.99%-3.1M	39.04%-2.4M	51.71%-1.27M	48.77%-3.94M	33.95%-2.62M	-71.73%-7.7M
Special items of earning before tax	----	----	----	----	----	----	----	----	----	-5.36%-27.53M
Earning before tax	2.43%-97.57M	0.69%-209.36M	14.39%-100M	27.74%-210.82M	19.53%-116.81M	-58.01%-291.74M	-167.88%-145.16M	8.84%-184.63M	53.16%-54.19M	-32.72%-202.53M
After-tax profit from continuing operations	2.43%-97.57M	0.69%-209.36M	14.39%-100M	27.74%-210.82M	19.53%-116.81M	-58.01%-291.74M	-167.88%-145.16M	8.84%-184.63M	53.16%-54.19M	-35.24%-202.53M
Earning after tax	2.43%-97.57M	0.69%-209.36M	14.39%-100M	27.74%-210.82M	19.53%-116.81M	-58.01%-291.74M	-167.88%-145.16M	8.84%-184.63M	53.16%-54.19M	-35.24%-202.53M
Profit attributable to shareholders	2.43%-97.57M	0.69%-209.36M	14.39%-100M	27.74%-210.82M	19.53%-116.81M	-58.01%-291.74M	-167.88%-145.16M	8.84%-184.63M	53.16%-54.19M	-62.17%-202.53M
Basic earnings per share	0.00%-0.02	0.00%-0.05	33.33%-0.02	28.57%-0.05	25.00%-0.03	-75.00%-0.07	-300.00%-0.04	20.00%-0.04	66.67%-0.01	16.67%-0.05
Diluted earnings per share	0.00%-0.02	0.00%-0.05	33.33%-0.02	28.57%-0.05	25.00%-0.03	-75.00%-0.07	-300.00%-0.04	20.00%-0.04	66.67%-0.01	16.67%-0.05
Currency Unit	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY
Accounting Standards	IAS	IAS	IAS	IAS	IAS	IAS	IAS	IAS	IAS	IAS
Audit Opinions	--	Unqualified Opinion	--	Unqualified Opinion	--	Unqualified Opinion	--	Unqualified Opinion	--	Unqualified Opinion
Auditor	--	Ernst & Young	--	Ernst & Young	--	Ernst & Young	--	Ernst & Young	--	Deloitte Guan Huang Chen Fang Certified Public Accountants

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Heat List

Overall

No Data

Investment Theme

Pharmaceutical Companies

Intraday-0.05%

02181 MABPHARM-B

MABPHARM-B Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow